Comparison between JFL Life Sciences IPO and Rhetan TMT IPO.
JFL Life Sciences IPO is a SME Fixed Price IPO proposed to list at NSE SME while Rhetan TMT IPO is a SME Fixed Price proposed to list at BSE SME.
| JFL Life Sciences IPO | Rhetan TMT IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Fixed Price |
| Listing At | NSE SME | BSE SME |
| Lead Managers | GYR Capital Advisors Pvt.Ltd. | Aryaman Financial Services Ltd. |
| Registrar | Kfin Technologies Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Econo Broking Pvt.Ltd. | Aryaman Capital Markets Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Anchor Investor | ||
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of JFL Life Sciences IPO is up to ₹17.25 Cr whereas the issue size of the Rhetan TMT IPO is up to ₹53.09 Cr. The final issue price of JFL Life Sciences IPO is ₹61.00 per share and of Rhetan TMT IPO is ₹70.00 per share.
| JFL Life Sciences IPO | Rhetan TMT IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ₹61.00 per share | ₹70.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 2000 shares | 2000 shares |
| Fresh Issue Size | 28,28,000 shares | 75,84,000 shares |
| Fresh Issue Size (Amount) | up to ₹17.25 Cr | up to ₹53.09 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 28,28,000 shares | 75,84,000 shares |
| Issue Size Total (Amount) | up to ₹17.25 Cr | up to ₹53.09 Cr |
JFL Life Sciences IPO opens on Aug 25, 2022, while Rhetan TMT IPO opens on Aug 22, 2022. The closing date of JFL Life Sciences IPO and Rhetan TMT IPO is Aug 30, 2022, and Aug 25, 2022, respectively.
| JFL Life Sciences IPO | Rhetan TMT IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Aug 25, 2022 | Aug 22, 2022 |
| Issue Close | Aug 30, 2022 | Aug 25, 2022 |
| Basis Of Allotment (Tentative) | Sep 05, 2022 | Aug 30, 2022 |
| Initiation of Refunds (Tentative) | Sep 06, 2022 | Sep 01, 2022 |
| Credit of Share (Tentative) | Sep 07, 2022 | Sep 02, 2022 |
| Listing date (Tentative) | Sep 08, 2022 | Sep 05, 2022 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
JFL Life Sciences IPO P/E ratio is 26.52, as compared to Rhetan TMT IPO P/E ratio of 63.64.
| JFL Life Sciences IPO | Rhetan TMT IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 92.52 | 99.62 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 67.47 | 62.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 26.52 | 63.64 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹67.09 Cr. | ₹148.75 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the JFL Life Sciences IPO Retail Individual Investors (RII) are offered 14,14,000 shares while in Rhetan TMT IPO retail investors are offered 14,14,000 shares. Qualified Institutional Buyers (QIB) are offered in JFL Life Sciences IPO and in Rhetan TMT IPO.
| JFL Life Sciences IPO | Rhetan TMT IPO | |
|---|---|---|
| Anchor Investor Reserveration | ||
| Market Maker Reserveration | 1,50,000 shares | 4,16,000 shares |
| QIB | ||
| NII | 14,14,000 shares | 37,92,000 shares |
| RII | 14,14,000 shares | 37,92,000 shares |
| Employee | ||
| Others | ||
| Total | 28,28,000 shares | 75,84,000 shares |
JFL Life Sciences IPO subscribed 8.93x in total, whereas Rhetan TMT IPO subscribed 1.47x.
| JFL Life Sciences IPO | Rhetan TMT IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | 6.19x | 2.18x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 11.66x | 0.76x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 8.93x | 1.47x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
